12 Papers
7 Citations
X. Ai is an academic researcher from Shanghai Chest Hospital. The author has contributed to research in topics: Medicine & Lung cancer. The author has an hindex of 2, co-authored 6 publications.
Chat about Author
Papers
A multicenter real-world study of tumor-derived DNA from pleural effusion supernatant in genomic profiling of advanced lung cancer.
TL;DR: Pleural effusion is commonly observed in advanced lung cancer and molecular profiling of PE represents a minimally invasive approach of detecting tumorigenicity in these patients.
7
Pyrotinib plus antiangiogenic agents for HER2-altered advanced non-small cell lung cancer: A retrospective real-world study.
TL;DR: This study aimed to assess the effectiveness and safety of pyrotinib plus antiangiogenic agents, including apatinib, anlotinib, and bevacizumab, in previously treated patients with HER2‐altered advanced NSCLC.
4
1044P Taxanes plus immunotherapy might be a potential option for HER2-altered NSCLC beyond first-line progression: A retrospective real-world study
TL;DR: In this article , the authors compared the efficacy of taxanes-based chemotherapy alone (C), and combined with angiogenesis inhibitors (C+A) or immune checkpoint inhibitors(C+I) for advanced non-small cell lung cancer (NSCLC).
2
P1.13-08 Distribution, Differences in Clinical Characteristics and Resistance Mechanism of ALK Variants in Chinese Lung Cancer Patients
Jiping Zhao,Qiang Li,Gen Lin,X. Dong,Lei Liu,Likun Chen,Jiyan Chen,Yong He,X. Ai,R. Guo,W. H. Wang,C. Xu,Runzhe Chen,Y. Xin,X. Xia +14 more
TL;DR: This data indicates that first-Line Lorlatinib Versus Crizotinib for Advanced Anaplastic Lymphoma Kinase-Positive (ALK) NonSmall Cell Lung Cancer may be a viable option for patients with advanced disease.
2